Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.

GLP-1 drugs indirectly reduce inflammation through weight loss. The meds can also activate certain T cells — white blood cells key to the immune system — which can have anti-inflammatory effects.

SALT LAKE CITY - LifeVantage Corporation (NASDAQ:LFVN), a $271 million market cap player in the health and wellness sector with impressive 79% gross profit margins, today announced the successful ...

"We believe the data from this study will demonstrate that the combination of MC4R + GLP-1/GIP agonists may result ... receptor-specific agonists, which activate receptor function, or receptor ...

Last Patient / Last Visit Completed Topline Data Readout Expected Later This Quarter CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc.

Olfactive Biosolutions’ Pivit™ GLP-1 Weight Management activates olfactory ... and what ligands activate or inhibit them.

Potential entry into high growth GLP-1 market of nearly $50 billion in 2024 ... TNF-α is located upstream of a cascade of molecular signals that induces inflammation and helps activate the process of ...

Olfactive Biosolutions’ Pivit™ GLP-1 Weight Management activates olfactory receptors ... tasks as active pharmaceutical ingredients or APIs, and what ligands activate or inhibit them. To learn more, ...